Director at Twist Bioscience (NASDAQ: TWST) receives 5,095-share award

Rhea-AI Filing Summary

Twist Bioscience director Robert P. Ragusa received an annual stock award of 5,095 common shares on February 5, 2026. The shares were granted at a price of $0 per share, reflecting a typical equity compensation grant for a non-employee director.

According to the vesting terms, 100% of this annual equity award will vest on the earlier of one year from the grant date or the first annual stockholder meeting after the grant, as long as he continues serving as a director. Following this grant, Ragusa beneficially owns 28,983 Twist Bioscience common shares in total, held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RAGUSA ROBERT P

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD.

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/05/2026		A		5,095(1)	A	$0	28,983	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. 100% of the Shares subject to the Annual Equity Award will vest upon the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the first annual meeting of stockholders following the date of grant, provided that the Non-Employee Director is a Service Provider on each vesting date.

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Robert Ragusa	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did TWST director Robert Ragusa report?

Robert P. Ragusa reported receiving 5,095 Twist Bioscience common shares as an annual equity award. The grant is a form of stock-based compensation for his board service and was recorded at a price of $0 per share, increasing his direct holdings to 28,983 shares.

When do Robert Ragusa’s new TWST shares vest?

The 5,095-share award vests in full on the earlier of one year from the grant date or the first annual stockholder meeting. Vesting requires Ragusa to remain a non-employee director and service provider through the applicable vesting date under the award’s terms.

How many TWST shares does Robert Ragusa own after this grant?

After the February 5, 2026 equity grant, Robert P. Ragusa beneficially owns 28,983 Twist Bioscience common shares directly. This total includes the newly granted 5,095-share annual award, subject to the disclosed vesting schedule tied to continued board service.

Was cash paid for the 5,095 TWST shares granted to Robert Ragusa?

No cash was paid for this grant; the 5,095 common shares were issued at a stated price of $0 per share. The award represents equity compensation for Ragusa’s role as a non-employee director, rather than an open-market stock purchase.

What is the nature of the TWST equity award reported by Robert Ragusa?

The filing describes the 5,095-share grant as an “Annual Equity Award” to a non-employee director. All shares in this award vest together once the time- and meeting-based condition is met, assuming Ragusa continues as a service provider to Twist Bioscience.